1	Early signals of significantly increased vaccine
2	breakthrough, decreased hospitalization rates, and less
3	severe disease in patients with COVID-19 caused by the
4	Omicron variant of SARS-CoV-2 in Houston, Texas
5	
6 7	Paul A. Christensen, ^{*,†,‡,§} Randall J. Olsen, ^{*,†,‡,§} S. Wesley Long, ^{*,†,‡,§} Richard Snehal, [†]
8	James J. Davis, ^{¶,**} Matthew Ojeda Saavedra, [†] Kristina Reppond, [†] Madison N. Shyer, [†]
9	Jessica Cambric, [†] Ryan Gadd, [†] Rashi M. Thakur, [†] Akanksha Batajoo, [†] Regan
10	Mangham, [†] Sindy Pena, [†] Trina Trinh, [†] Jacob C. Kinskey, [†] Guy Williams, [†] Robert
11	Olson, ^{¶,**} Jimmy Gollihar, [‡] James M. Musser ^{†,‡,§,††}
12	
13	*Contributed equally;
14	[†] Laboratory of Human Molecular and Translational Human Infectious Diseases and
15	[‡] Laboratory of Antibody Discovery and Accelerated Protein Therapeutics, Center for
16	Infectious Diseases, Houston Methodist Research Institute and Department of
17	Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas;
18	$^{\$}$ Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New
19	York, New York;

- ²⁰ [¶]Consortium for Advanced Science and Engineering, University of Chicago, Chicago,
- 21 Illinois;
- ^{**}Computing, Environment and Life Sciences, Argonne National Laboratory, Lemont,
- 23 Illinois;
- 24
- ¹⁷Address correspondence to James M. Musser, M.D., Ph.D., Department of Pathology
- 26 and Genomic Medicine, Houston Methodist Research Institute, 6565 Fannin Street,
- 27 Suite B490, Houston, Texas 77030. Tel: 713.441.5890, E-mail:
- 28 jmmusser@houstonmethodist.org
- 29
- 30 Running head: Omicron variant in Houston, Texas
- 31

- 33
- 34 Funding: This project was supported by the Houston Methodist Academic Institute
- 35 Infectious Diseases Fund; and in part with funds from the National Institute of Allergy
- 36 and Infectious Diseases, National Institutes of Health, Department of Health and Human
- 37 Services, under Contract No. 75N93019C00076 (J.J.D.).

- 39 Number of text pages: 13
- 40 Number of figures: 2
- 41 Number of tables: 2

³² Disclosures: None.

42 Abstract

43 Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the 44 COVID-19 pandemic. The recently described variant of concern designated Omicron (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of 45 46 COVID-19 cases in many countries. Because Omicron was recognized very recently, many knowledge gaps exist about its epidemiology, clinical severity, and disease 47 48 course. A comprehensive genome sequencing study of SARS-CoV-2 in the Houston 49 Methodist healthcare system identified 1.313 symptomatic patients with infections 50 caused by Omicron from late November 2021 through December 20, 2021. Omicron 51 very rapidly increased in only three weeks to cause 90% of all new COVID-19 cases. 52 Compared to patients infected with either Alpha or Delta variants in our healthcare 53 system. Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. 54 55 Omicron patients required less intense respiratory support and had a shorter length of 56 hospital stay, consistent with decreased disease severity. Although the number of 57 Omicron patients we studied is relatively small, in the aggregate the data document the unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron 58 59 variant in metropolitan Houston, and provide information about disease character.

60

61

63 [Introduction]

- 64
- 65

66 Over the last 14 months, the Alpha and Delta variants of concern (VOCs) of SARS-

- 67 CoV-2 have caused two distinct COVID-19 disease surges in the United States,
- 68 Southeast Asia, Europe, and elsewhere (https://www.cdc.gov/coronavirus/2019-

69 <u>ncov/cases-updates/variant-surveillance/variant-info.html</u>, last accessed December 30,

70 2021; https://www.gov.uk/government/collections/new-sars-cov-2-variant, last accessed

71 December 30, 2021)¹, and remodeled the landscape of human behavior and many

societies. Delta replaced the Alpha variant as the cause of virtually all COVID-19 in

73 many countries (https://www.who.int/publications/m/item/weekly-epidemiological-

74 update-on-covid-19---13-july-2021, last accessed August 18, 2021;

75 <u>https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditions</u>

76 and diseases/bulletins/coronaviruscovid19infectionsurveypilot/9july2021, last accessed

77 August 18, 2021).

78 At the start of the pandemic almost two years ago, the Houston Methodist

79 healthcare system instituted a comprehensive and integrated population genomics

80 project designed to sequence all SARS-CoV-2 samples causing COVID-19 in patients

81 cared for at our facilities, which include eight hospitals located throughout the

82 metroplex. The project was implemented when the initial Houston Methodist COVID-19

case was diagnosed at the end of February 2020, and has continued unabated²⁻⁶. This

84 project was facilitated by the existence of a single large diagnostic laboratory that

serves the entire system and is seamlessly integrated with a research institute with

86 extensive genomics expertise and capacity. A key goal was to comprehensively map

87 the population genomics, trajectory, and other features of the pandemic in metropolitan

Houston with a population size of approximately 7.2 million. Houston is the fourth
largest city in the United States, the most ethnically diverse metropolitan area in the
country, and is a major port of entry. To date, SARS-CoV-2 genomes have been
sequenced from greater than 70,000 patient samples. Many features of four distinct
SARS-CoV-2 waves in Houston have been described²⁻⁶.

93 The successes of rapid SARS-CoV-2 vaccine development and documented efficacy, coupled with the significant downturn of the disease wave caused by Delta in 94 Houston and elsewhere in fall, 2021⁶, suggested that the pandemic was abating. 95 96 However, the identification of a new VOC designated B.1.1.529 and commonly known as Omicron that has spread rapidly in South Africa and the UK has tempered this 97 optimism⁷⁻⁹. Inasmuch as Omicron was recognized very recently, and much is not 98 known about its epidemiology and clinical characteristics and course, we used our 99 100 integrated infrastructure in an effort to address some pertinent knowledge gaps. 101 Genome sequencing identified 1,313 COVID-19 patients with symptomatic disease 102 caused by Omicron in the Houston Methodist healthcare system beginning in late November 2021 and ending December 20, 2021. In three weeks Omicron spread 103 104 throughout the Houston metropolitan region and became the cause of 90% of new COVID-19 cases. Although the number of our Omicron patients is relatively small, 105 106 compared to patients infected with either Alpha or Delta variants and cared for in our 107 system, significantly fewer Omicron patients were hospitalized, and those who were 108 hospitalized required significantly less intense respiratory support and had a shorter 109 length of stay. We cautiously interpret our findings to be consistent with decreased 110 disease severity among Houston Methodist Omicron patients. Many factors undoubtedly

111	have contributed, including but not limited to increased vaccination uptake, population
112	immunity, and patient demographics such as younger age. The extent to which our
113	findings translate to other cities and other patient populations, including children, is
114	unknown. Our study was not designed to address possible intrinsic differences in
115	virulence of Omicron compared to Alpha, Delta, and other VOCs. We believe this topic
116	remains an open question that warrants further investigation.
117	
118	

Materials and Methods

120

121 Patient Specimens

122

123 Specimens were obtained from patients registered at Houston Methodist facilities (e.g., 124 hospitals and urgent care centers), and institutions in the Houston metropolitan region 125 that use our laboratory services. The great majority of individuals had signs or 126 symptoms consistent with COVID-19 disease. For analyses focusing on patients with 127 COVID-19 caused by the Omicron variant, samples obtained from November 27, 2021 128 through December 20, 2021 were used. This time frame was chosen because it 129 represents the period during which an Omicron variant was first identified in our 130 healthcare system and the last date of specimen collection used to generate genome 131 sequence data for this manuscript. For analyses comparing features of patients infected 132 with the Omicron VOC and Alpha and Delta VOCs, all patients documented to be

- infected with these variants in the Houston Methodist system were studied. The study
- included 36,793 unique patients identified in this time frame for whom we had SARS-
- 135 CoV-2 genome sequences. The work was approved by the Houston Methodist
- 136 Research Institute Institutional Review Board (IRB1010-0199).
- 137
- 138 SARS-CoV-2 Molecular Diagnostic Testing
- 139
- 140 Specimens obtained from symptomatic patients with a suspicion for COVID-19 disease
- 141 were tested in the Molecular Diagnostics Laboratory at Houston Methodist Hospital
- using assays granted Emergency Use Authorization (EUA) from the FDA
- 143 (https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-
- 144 <u>diagnostic-testing-sars-cov-2#offeringtests</u>, last accessed June 7, 2021). Multiple
- 145 molecular testing platforms were used, including the COVID-19 test or RP2.1 test with
- 146 BioFire Film Array instruments, the Xpert Xpress SARS-CoV-2 test using Cepheid
- 147 GeneXpert Infinity or Cepheid GeneXpert Xpress IV instruments, the Cobas SARS-
- 148 CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay
- using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic
- 150 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system,
- and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were
- 152 performed on material obtained from nasopharyngeal swabs immersed in universal
- transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or
- sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen

- 155 collection methods were used (https://vimeo.com/396996468/2228335d56, last
- 156 accessed June 7, 2021).
- 157

158 SARS-CoV-2 Genome Sequencing, Genome Analysis, and Identification of

- 159 Variants
- 160
- 161 We sequenced the SARS-CoV-2 genome of >90% of all positive cases in the Houston
- 162 Methodist healthcare system during the period studied. Libraries for whole SARS-CoV-2
- 163 genome sequencing were prepared according to version 4
- 164 (https://community.artic.network/t/sars-cov-2-version-4-scheme-release/312, last
- accessed August 19, 2021) of the ARTIC nCoV-2019 sequencing protocol. The semi-
- automated workflow used has been described previously²⁻⁶. Sequence reads were
- 167 generated with an Illumina NovaSeq 6000 instrument.
- 168 Viral genomes were assembled with the BV-BRC SARS-Cov2 assembly service
- 169 (https://www.bv-brc.org/app/ComprehensiveSARS2Analysis, last accessed June 7,
- 170 2021, requires registration). The pipeline currently uses seqtk version 1.3-r117 for
- sequence trimming (<u>https://github.com/lh3/seqtk.git</u>) and minimap version 2.17 for
- aligning reads against the Wuhan-Hu-1 (NC_045512.2) reference genome. Samtools
- version 1.11 was used for sequence and file manipulation, where maximum depth and
- 174 minimum depth parameters in mpileup were set to 8,000 and 3, respectively. iVar
- version 1.3.1 was used for primer trimming and variant calling. Genetic lineages,
- 176 VOCs, and variants of interest (VOIs) were identified based on genome sequence data
- and designated by Pangolin v. 3.1.17 with pangoLEARN module 2021-12-06

- 178 (https://cov-lineages.org/resources/pangolin.html, last accessed December 12, 2021).
- 179 Genome data used in this study have been deposited to GISAID <u>www.gisaid.org</u>.
- 180

181 S-Gene Target-Failure Assay

- 182
- 183 An S-gene target-failure (SGTF) assay (TaqPath COVID-19 Combo Kit Thermo Fisher,
- 184 Inc.), was used as a surrogate marker for the Omicron VOC for some specimens
- collected between December 18, 2021 and December 22, 2021. From November 1,
- 186 2021 onward, only Delta and Omicron were circulating in metropolitan Houston, as
- documented by whole-genome sequence data. Thus, samples with S-gene target failure
- 188 were classified as Omicron, whereas samples yielding amplification of the S-gene were
- 189 classified as a Delta variant.
- 190
- 191 Patient Metadata and Geospatial Analysis
- 192

Patient metadata were acquired from the electronic medical record by standard
informatics methods. Figures showing geospatial distribution of spread for Omicron

195 were generated with Tableau version 2021.2.7 (Tableau Software, LLC, Seattle, WA)

using patient home address zip codes. A vaccination breakthrough case was defined as

- a PCR-positive sample from a patient obtained greater than 14 days after full
- 198 vaccination (e.g., both doses of the Pfizer or Moderna mRNA vaccines) was completed.
- 199 A booster vaccination breakthrough case was defined as a PCR-positive sample from a
- 200 patient obtained greater than 14 days after receiving a third vaccine dose. For some

201	cases, manual chart review was conducted to resolve discrepancies or clarify
202	ambiguities.
203	
204	
205	Results
206	
207	Omicron Epidemiologic Wave
208	
209	The first Houston Methodist patient infected with an Omicron variant was identified at
210	the end of November 2021, a time when the Delta VOC was responsible for all COVID-
211	19 cases in metropolitan Houston ⁶ . During this period, the metropolitan area was
212	experiencing a steady decrease in total number of new COVID-19 cases (Figure 1,
213	Figure 2).
214	Omicron increased in frequency unusually rapidly over a three-week period in
215	December (Figure 1, Figure 2). By December 20, the genome sequence data showed
216	that Omicron accounted for >90% of all new COVID-19 cases in our healthcare system
217	(Figure 2). This represents the fifth wave of COVID-19 cases in metropolitan Houston
218	(Figure 1). The estimated case doubling time during this three-week period was
219	approximately 1.8 days (Figure 2), which means that Omicron increased in relative
220	frequency approximately three times faster than Delta had increased in our area ⁶ , an
221	unprecedented trajectory for SARS-COV-2 infections.
222	Consistent with extensive infections caused by Omicron in southern Africa and
223	elsewhere (https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-

224 <u>classifications.html</u>, last accessed December 28, 2021;

225 https://www.gov.uk/government/collections/new-sars-cov-2-variant, last accessed

December 28, 2021), several patients had very recent travel histories to countries with a high prevalence of this VOC, suggesting acquisition of virus by some cases from abroad and importation into Houston. However, the great majority of Omicron patients had no documented travel outside the US and undoubtedly acquired the infection domestically, either in Houston or elsewhere.

231 To understand the geospatial distribution of Omicron in metropolitan Houston, 232 patient metadata were acquired from the electronic medical record by standard informatics methods, and home address zip codes were used to visualize virus spread 233 234 (Figure 2). The 1,313 Houston Methodist patients infected with Omicron during this 235 period were distributed widely throughout metropolitan Houston, with 200 different zip 236 codes represented (Figure 2). The widespread distribution of Omicron in the Houston 237 metroplex in an extremely short period of time reflects the ability of this variant to spread 238 unusually rapidly and effectively between individuals, and cause symptomatic disease. 239

240 Comparison of Omicron, Alpha, and Delta COVID-19 Cases

241

There is a considerable lack of detailed information about patients in the United States and elsewhere with COVID-19 caused by the Omicron VOC. We compared available metadata for all Houston Methodist patients infected with Omicron, Alpha, and Delta VOCs (**Table 1, Table 2**). The populations differed significantly in many characteristics,

including median age, hospital admission rates, maximum respiratory support, rate of
vaccine breakthrough, and median length of stay (**Table 1, Table 2**).

Patients infected with Omicron were significantly younger than Alpha and Delta
patients (**Table 1, Table 2**). Importantly, Omicron patients were hospitalized significantly
less frequently than patients infected with either the Alpha or Delta variants, and had a

significantly shorter median hospital length of stay (**Table 1, Table 2**).

252 We next analyzed Omicron vaccine breakthrough cases (Table 1, Table 2). We 253 found 675 of the 1313 total Omicron patients (51.4%) for whom we have whole genome 254 sequence data met the CDC definition of vaccine breakthrough cases (Table 1, Table 255 2). There was no simple relationship between the time elapsed since administration of 256 the second vaccination dose and the date of vaccination breakthrough. These 675 257 patients received either two doses of the Pfizer-BioNTech BNT162b2 (n = 485, 72%) or 258 Moderna mRNA-1273 (n = 157, 23%), or one dose of J&J/Janssen JNJ-78436735 (n = 157, 23%) 259 33, 5%) vaccine. This distribution reflects the majority use of BNT162b2 vaccination 260 doses in our health system. Compared to either Alpha or Delta patients, a significantly greater percentage of patients with breakthrough cases was caused by the Omicron 261 262 VOC (51.4% compared to 3.2% and 24.3% for Alpha and Delta VOCs, respectively) 263 (Table 1, Table 2). We next analyzed individuals with breakthrough cases after 264 receiving a third (booster) dose of either the Pfizer-BioNTech BNT162b2 or Moderna 265 mRNA-1273 vaccine. We found that 140 (10.7%) of the 1,313 Omicron patients met this 266 criteria. Consistent with Omicron causing a significantly increased number of vaccine 267 breakthrough cases, it has been reported that this variant has reduced sensitivity to

268	antibody neutralization in vitro, likely in large part due to the extensive number of amino
269	acid and other structural changes occurring in Omicron spike protein ¹⁰⁻³¹ .
270	
271	An Omicron Sublineage With Spike Protein Polymorphism L452R
272	
273	The L452R amino acid change in spike protein of SARS-CoV-2 has arisen by
274	convergent evolution in multiple genetic lineages throughout the course of the
275	pandemic, most notably in the Delta VOC. L452R is located in the receptor binding
276	domain of spike protein and has been associated with decreased antibody
277	neutralization, escape from cell mediated immunity, and increased affinity for the ACE2
278	receptor ^{32, 33} . L452R was present in samples of Omicron collected in South Africa as
279	early as November 11, 2021. We found that all 43 specimens collected over the first
280	nine days after we identified Omicron in Houston Methodist patients had the 452R
281	amino acid replacement. Our first L452 isolate was collected on day 10. By day 16, over
282	half the Omicron isolates collected were L452, and the proportion of 452R isolates
283	continued to diminish. Among the 65,109 Omicron samples deposited in GISAID as of
284	28 December 2021, only 727 (1.1%) have the 452R amino acid replacement and over
285	half of these were from Houston Methodist patients. The initial high prevalence of
286	Omicron containing 452R in spike protein in our population may represent a founder
287	effect of the original genotype introduced into Houston.
288	

289 Spike-Gene Target-Failure Assay

290

291	To estimate Omicron variant frequency in patient samples not yet sequenced, we
292	performed the TaqPath COVID-19 Combo Kit assay (ThermoFisher) on 657 samples
293	collected from symptomatic patients between December 18, 2021 and December 22,
294	2021. In total, 604 (91.9%) of patient samples yielded a RT-PCR result with S-gene
295	target-failure indicative of the Omicron variant. These data are consistent with the
296	increasing frequency of new cases of COVID-19 caused by Omicron in our population
297	(Figure 2).
298	
299	Lack of Omicron Variant BA.2 in Houston Methodist Samples
300	
301	The BA.2 Omicron sublineage was first identified in November 2021 in Australia in a
302	patient who had traveled to South Africa (https://github.com/cov-lineages/pango-
303	designation/issues/359; last accessed December 30, 2021). This sublineage does not
304	have the full set of polymorphisms characteristic of BA.1 (B.1.1.529) and also has
305	additional mutations unique to it (<u>https://github.com/cov-lineages/pango-</u>
306	designation/issues/361; last accessed December 30, 2021). One important difference is
307	that sublineage BA.2 lacks the spike protein deletion at amino acid 69/70 which means
308	that it will not be detected by the SGTF assay. We inspected all full genome sequences
309	present in our large database and this sublineage was not present. This includes all
310	specimens taken from symptomatic patients or asymptomatic individuals. Thus, it is
311	likely that routine use of an SGTF assay in our population will identify all or virtually all
312	patients infected with Omicron.

314 **Discussion**

315

316	In this work, we describe information relevant to the surging Omicron wave in
317	metropolitan Houston. In three weeks, Omicron was first identified in our population and
318	rapidly increased to cause 90% of all new COVID-19 cases, with an estimated case
319	doubling time of 1.8 days. The study was based on genome sequence analysis of 1,313
320	Omicron samples taken from socioeconomically, geographically, and ethnically diverse
321	symptomatic patients. Several key findings were made, including (i) the Omicron VOC
322	rapidly increased as a cause of COVID-19 and spread throughout the metroplex in an
323	unusually short period of time, far faster than any other SARS-CoV-2 variant; (ii)
324	Omicron caused significantly more vaccine breakthrough cases than the Alpha or Delta
325	VOCs; (iii) Omicron patients were significantly younger than Alpha or Delta patients; (iv)
326	significantly fewer Omicron patients required hospitalization compared to Alpha and
327	Delta patients; (v) the median length of stay for hospitalized Omicron patients was
328	significantly shorter than for Alpha and Delta patients, and consistent with this
329	observation, the maximum respiratory support required for Omicron patients was
330	significantly less than for Alpha or Delta patients. Our findings are largely consistent
331	with many aspects of Omicron data reported from the UK, South Africa, and Canada ^{7-9,}
332	³⁴⁻³⁶ and are consistent with experimental animal infection data suggesting that Omicron
333	causes less severe disease in mice and hamsters ³⁷⁻⁴⁰ . This study was facilitated by a
334	comprehensive and integrated population genomics and epidemiology project ²⁻⁶
335	implemented at the end of February, 2020, when the initial COVID-19 case was
336	diagnosed in the Houston Methodist healthcare system.

337 Because we sequence the genome of approximately 90% of SARS-CoV-2 338 causing COVID-19 in our diverse Houston Methodist patient population, and have done 339 so for almost two years, this means we are continuously monitoring the composition of 340 this virus in a major US metroplex. This affords us the opportunity to rapidly assess 341 changes in SARS-CoV-2 population genomic structure in the fourth largest city in the 342 US. However, our study has several limitations. Although we sequenced the genomes of SARS-CoV-2 causing 90% of all Houston Methodist COVID-19 cases in the study 343 344 period, this sample represents only approximately 5% of cases reported in the 345 metropolitan region. Our patient population will underrepresent some demographic 346 groups, for example homeless individuals and pediatric patients. The samples 347 sequenced in this study were obtained from symptomatic individuals, which means that 348 it is possible that we failed to identify Omicron subvariants or features preferentially 349 represented in asymptomatic individuals. It is likely that our study included some 350 patients where Omicron was detected on hospital admission but was incidental to the 351 primary cause of admission.

352 In the aggregate, our data add critical new information to features of Omicron 353 genomic epidemiology and patient characteristics in the US. Further, the present study 354 highlights the importance of analyzing SARS-CoV-2 genome data integrated with 355 patient metadata and stresses the need to continue to do this in near-real time as the 356 Omicron surge continues, the virus evolves, and new variants with potentially altered 357 fitness and biomedically relevant phenotypes are generated. Analyses of this type are 358 also important in the context of vaccine formulation and long COVID, an increasing 359 health and economic problem globally. Finally, the strategy we have used in this and

- 360 previous studies²⁻⁶ are readily applicable to future infectious diseases problems that
- 361 warrant special attention.

362

363 Acknowledgments

364

365	We thank Drs. Marc Boom and Dirk Sostman for their ongoing support, and Dr. Sasha
366	M. Pejerrey for editorial contributions. The research was supported by the Houston
367	Methodist Academic Institute Infectious Diseases Fund and many generous Houston
368	philanthropists. The funders had no role in the design and conduct of the study;
369	collection, management, analysis, and interpretation of the data; preparation, review, or
370	approval of the manuscript; and decision to submit the manuscript for publication.
371	
372	We declare that we have no conflict of interest.
373	
374	
375	Author Contributions
376	
377	P.A.C., R.J.O., S.W.L., and J.M.M. had full access to all study data and take
378	responsibility for the integrity of the data and the accuracy of the data analysis; concept
379	and design by J.M.M., P.A.C., R.J.O., and S.W.L; data acquisition, analysis, or

interpretation by all authors; drafting of the manuscript by all authors; statistical analysis

- by P.A.C.; funding obtained by J.M.M. and J.J.D.; and overall supervision by J.M.M.
- 382 P.A.C., R.J.O., and S.W.L. contributed equally and are co-first authors.

383

385 **References**

- [1] Dhar MS, Marwal R, Radhakrishnan V, Ponnusamy K, Jolly B, Bhoyar RC, et al.:
- 387 Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in
- 388 Delhi, India. medRxiv 2021. [Preprint]. doi:2021.2006.2002.21258076
- [2] Long SW, Olsen RJ, Christensen PA, Bernard DW, Davis JJ, Shukla M, Nguyen M,
- 390 Saavedra MO, Yerramilli P, Pruitt L, Subedi S, Kuo HC, Hendrickson H, Eskandari G,
- Nguyen HAT, Long JH, Kumaraswami M, Goike J, Boutz D, Gollihar J, McLellan JS,
- 392 Chou CW, Javanmardi K, Finkelstein IJ, Musser JM: Molecular Architecture of Early
- 393 Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major
- 394 Metropolitan Area. mBio 2020, 11
- [3] Musser JM, Olsen RJ, Christensen PA, Long SW, Subedi S, Davis JJ, Gollihar J:
- 396 Rapid, widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in
- Houston, TX, revealed by 8,857 genome sequences. medRxiv 2021. [Preprint].
- 398 doi:2021.2003.2016.21253753
- [4] Olsen RJ, Christensen PA, Long SW, Subedi S, Hodjat P, Olson R, Nguyen M,
- 400 Davis JJ, Yerramilli P, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd
- 401 R, Thakur RM, Batajoo A, Finkelstein IJ, Gollihar J, Musser JM: Trajectory of Growth of
- 402 Severe Acute Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Houston,
- Texas, January through May 2021, Based on 12,476 Genome Sequences. Am J Pathol
- 404 2021, Oct;191(10):1754-1773.
- [5] Long SW, Olsen RJ, Christensen PA, Subedi S, Olson R, Davis JJ, Saavedra MO,
- 406 Yerramilli P, Pruitt L, Reppond K, Shyer MN, Cambric J, Finkelstein IJ, Gollihar J,
- 407 Musser JM: Sequence Analysis of 20,453 SARS-CoV-2 Genomes from the Houston

- 408 Metropolitan Area Identifies the Emergence and Widespread Distribution of Multiple
- 409 Isolates of All Major Variants of Concern. Am J Pathol 2021, Jun;191(6):983-992
- 410 [6] Christensen PA, Olsen RJ, Long SW, Subedi S, Davis JJ, Hodjat P, Walley DR,
- 411 Kinskey JC, Saavedra MO, Pruitt L, Reppond K, Shyer MN, Cambric J, Gadd R, Thakur
- 412 RM, Batajoo A, Mangham R, Pena S, Trinh T, Yerramilli P, Nguyen M, Olson R, Snehal
- 413 R, Gollihar J, Musser JM: Delta Variants of SARS-CoV-2 Cause Significantly Increased
- 414 Vaccine Breakthrough COVID-19 Cases in Houston, Texas. Am J Pathol 2021, Nov
- 415 11;S0002-9440(21)00480-6.
- 416 [7] Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Lessells RJ, et al.: Rapid
- 417 epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. medRxiv
- 418 2021. [Preprint]. doi:2021.2012.2019.21268028
- [8] Elliott P, Bodinier B, Eales O, Wang H, Haw D, Elliott J, Whitaker M, Jonnerby J,
- 420 Tang D, Walters CE, Atchison C, Diggle PJ, Page AJ, Trotter AJ, Ashby D, Barclay W,
- 421 Taylor G, Ward H, Darzi A, Cooke GS, Chadeau-Hyam M, Donnelly CA: Rapid increase
- 422 in Omicron infections in England during December 2021: REACT-1 study. medRxiv
- 423 2021. [Preprint]. doi:2021.2012.2022.21268252
- 424 [9] Sheikh AK, Steven; Woolhouse, Mark; McMenamin, Jim; Robertson, Chris. : Severity
- 425 of Omicron variant of concern and vaccine effectiveness against symptomatic disease:
- 426 national cohort with nested test negative design study in Scotland. The University of
- 427 Edinburgh 2021
- [10] Meng B, Ferreira I, Abdullahi A, Kemp SA, Goonawardane N, Papa G, Fatihi S,
- 429 Charles O, Collier D, Collaboration C-NBC-, Consortium TGtPJ, Choi J, Hyeon Lee J,
- 430 MIcochova P, James L, Doffinger R, Thukral L, Sato K, Gupta RK: SARS-CoV-2

- 431 Omicron spike mediated immune escape, infectivity and cell-cell fusion. bioRxiv 2021.
- 432 [Preprint]. doi:2021.2012.2017.473248
- [11] Zeng C, Evans JP, Qu P, Faraone J, Zheng Y-M, Carlin C, Bednash JS, Zhou T,
- 434 Lozanski G, Mallampalli R, Saif LJ, Oltz EM, Mohler P, Xu K, Gumina RJ, Liu S-L:
- 435 Neutralization and Stability of SARS-CoV-2 Omicron Variant. bioRxiv 2021. [Preprint].
- 436 doi:2021.2012.2016.472934
- 437 [12] Jacobsen H, Strengert M, Maass H, Ynga Durand MA, Kessel B, Harries M, Rand
- 438 U, Abassi L, Kim Y, Lueddecke T, Hernandez P, Ortmann J, Heise J-K, Castell S,
- 439 Gornyk D, Gloeckner S, Melhorn V, Lange B, Dulovic A, Haering J, Junker D,
- 440 Schneiderhan-Marra N, Poehlmann S, Hoffmann M, Krause G, Cicin-Sain L: Diminished
- 441 neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-
- 442 based COVID-19 vaccinations. medRxiv 2021. [Preprint].
- 443 doi:2021.2012.2021.21267898
- [13] Eggink D, Andeweg SP, Vennema H, van Maarseveen N, Vermaas K, Vlaemynck
- B, Schepers R, van Gageldonk-Lafeber AB, van den Hof S, Reusken CBEM, Knol MJ:
- 446 Increased risk of infection with SARS-CoV-2 Omicron compared to Delta in vaccinated
- and previously infected individuals, the Netherlands, 22 November to 19 December
- 448 2021. medRxiv 2021. [Preprint]. doi:2021.2012.2020.21268121
- [14] Edara V-V, Manning KE, Ellis M, Lai L, Moore KM, Foster SL, Floyd K, Davis-
- 450 Gardner ME, Mantus G, Nyhoff LE, Bechnack S, Alaaeddine G, Naji A, Samaha H, Lee
- 451 M, Bristow L, Hussaini L, Ciric CR, Nguyen P-V, Gagne M, Roberts-Torres J, Henry AR,
- 452 Godbole S, Grakoui A, Sexton M, Piantadosi A, Waggoner JJ, Douek DC, Anderson EJ,
- 453 Rouphael N, Wrammert J, Suthar MS: mRNA-1273 and BNT162b2 mRNA vaccines

- 454 have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. bioRxiv
- 455 2021. [Preprint]. doi:2021.2012.2020.473557
- 456 [15] Zou j, Xia H, Xie X, Kurhade C, Machado RR, Weaver SC, Ren P, Shi P-Y:
- 457 Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.
- 458 bioRxiv 2021. [Preprint]. doi:2021.2012.2020.473584
- [16] Ikemura N, Hoshino A, Higuchi Y, Taminishi S, Inaba T, Matoba S: SARS-CoV-2
- 460 Omicron variant escapes neutralization by vaccinated and convalescent sera and
- therapeutic monoclonal antibodies. medRxiv 2021. [Preprint].
- 462 doi:2021.2012.2013.21267761
- [17] Dejnirattisai W, Shaw RH, Supasa P, Liu C, Stuart AS, Pollard AJ, Liu X, Lambe T,
- 464 Crook D, Stuart DI, Mongkolsapaya J, Nguyen-Van-Tam JS, Snape MD, Screaton GR,
- 465 group tC-Cs: Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by
- 466 post-immunisation serum. medRxiv 2021. [Preprint]. doi:2021.2012.2010.21267534
- 467 [18] Cameroni E, Saliba C, Bowen JE, Rosen LE, Culap K, Pinto D, et al.: Broadly
- 468 neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. bioRxiv 2021.
- 469 [Preprint]. doi:2021.2012.2012.472269
- [19] Liu L, Iketani S, Guo Y, Chan JF-W, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair
- 471 MS, Yu J, Chik KK-H, Yuen TT-T, Yoon C, To KK-W, Chen H, Yin MT, Sobieszczyk ME,
- 472 Huang Y, Wang HH, Sheng Z, Yuen K-Y, Ho DD: Striking Antibody Evasion Manifested
- 473 by the Omicron Variant of SARS-CoV-2. bioRxiv 2021. [Preprint].
- 474 doi:2021.2012.2014.472719
- [20] Planas D, Saunders N, Maes P, Benhassine FG, Planchais C, Porrot F, Staropoli I,
- 476 Lemoine F, Pere H, Veyer D, Puech J, Rodary J, Bolland WH, Buchrieser J, Baele G,

- 477 Dellicour S, Raymenants J, Gorissen S, Geenen C, Vanmechelen B, Wawina T, Marti J,
- 478 Cuypers L, Seve A, Hocqueloux L, Prazuck T, Loriere ES, REY F, Bruel T, Mouquet H,
- 479 Andre E, Schwartz O: Considerable escape of SARS-CoV-2 variant Omicron to
- 480 antibody neutralization. bioRxiv 2021. [Preprint]. doi:2021.2012.2014.472630
- 481 [21] Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, Gower C, Kall
- 482 M, Groves N, O'Connell A-M, Simons D, Blomquist PB, Zaidi A, Nash S, Aziz NIBA,
- 483 Thelwall S, Dabrera G, Myers R, Amirthalingam G, Gharbia S, Barrett JC, Elson R,
- Ladhani SN, Ferguson N, Zambon M, Campbell CN, Brown K, Hopkins S, Chand M,
- 485 Ramsay M, Bernal JL: Effectiveness of COVID-19 vaccines against the Omicron
- 486 (B.1.1.529) variant of concern. medRxiv 2021. [Preprint]. doi:2021.2012.2014.21267615
- 487 [22] Yu X, Wei D, Xu W, Li Y, Li X, Zhang X, Qu J, Yang Z, Chen E: Reduced sensitivity
- 488 of SARS-CoV-2 Omicron variant to booster-enhanced neutralization. medRxiv 2021.
- 489 [Preprint]. doi:2021.2012.2017.21267961
- 490 [23] Cele S, Jackson L, Khan K, Khoury DS, Moyo-Gwete T, Tegally H, Scheepers C,
- 491 Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y, Jule Z,
- 492 Reedoy K, Cromer D, San JE, Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI, Karim
- 493 SSA, Hanekom W, NGS-SA, Team C-K, von Gottberg A, Bhiman J, Lessells RJ, Moosa
- 494 M-YS, Davenport MP, de Oliveira T, Moore PL, Sigal A: SARS-CoV-2 Omicron has
- 495 extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires
- 496 ACE2 for infection. medRxiv 2021. [Preprint]. doi:2021.2012.2008.21267417
- 497 [24] Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An
- 498 R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X,
- 499 Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS: B.1.1.529

- 500 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes.
- 501 bioRxiv 2021. [Preprint]. doi:2021.2012.2007.470392
- 502 [25] Hansen CH, Schelde AB, Moustsen-Helms IR, Emborg H-D, Krause TG, Moelbak
- 503 K, Valentiner-Branth P, Institut TIDPGaSS: Vaccine effectiveness against SARS-CoV-2
- infection with the Omicron or Delta variants following a two-dose or booster BNT162b2
- or mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021. [Preprint].
- 506 doi:2021.2012.2020.21267966
- 507 [26] Syed AM, Ciling A, Khalid MM, Sreekumar B, Kumar GR, Silva I, Milbes B, Kojima
- 508 N, Hess V, Shacreaw M, Lopez L, Brobeck M, Turner F, Spraggon L, Taha TY, Tabata
- 509 T, Chen IP, Ott M, Doudna JA: Omicron mutations enhance infectivity and reduce
- 510 antibody neutralization of SARS-CoV-2 virus-like particles. medRxiv 2021. [Preprint].
- 511 doi:2021.2012.2020.21268048
- 512 [27] Sheward DJ, Kim C, Ehling RA, Pankow A, Castro Dopico X, Martin DP, Reddy ST,
- 513 Dillner J, Karlsson Hedestam GB, Albert J, Murrell B: Variable loss of antibody potency
- against SARS-CoV-2 B.1.1.529 (Omicron). bioRxiv 2021. [Preprint].
- 515 doi:2021.2012.2019.473354
- 516 [28] Haveri A, Solastie A, Ekström N, Österlund P, Nohynek H, Nieminen T, Palmu AA,
- 517 Melin M: Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA
- 518 vaccination in health care workers and elderly subjects and response to a single dose in
- 519 previously infected adults. medRxiv 2021. [Preprint]. doi:2021.2012.2022.21268273
- 520 [29] Arien KK, Heyndrickx L, Michiels J, Vereecken K, Van Lent K, Coppens S, Pannus
- 521 P, Martens GA, Van Esbroeck M, Goossens ME, Marchant A, Bartholomeeusen K,
- 522 Desombere I: Three doses of the BNT162b2 vaccine confer neutralising antibody

- 523 capacity against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern. medRxiv
- 524 2021. [Preprint]. doi:2021.2012.2023.21268316
- [30] Willett BJ, Grove J, MacLean O, Wilkie C, Logan N, De Lorenzo G, et al.: The
- 526 hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change,
- 527 vaccine escape and a switch in cell entry mechanism. medRxiv 2022. [Preprint].
- 528 doi:2022.2001.2003.21268111
- [31] Boschi C, Colson P, Bancod A, Moal V, La Scola B: Omicron variant escapes
- therapeutic mAbs contrary to eight prior main VOC. bioRxiv 2022. [Preprint].
- 531 doi:2022.2001.2003.474769
- [32] Motozono C, Toyoda M, Zahradnik J, Saito A, Nasser H, Tan TS, Ngare I, Kimura I,
- 533 Uriu K, Kosugi Y, Yue Y, Shimizu R, Ito J, Torii S, Yonekawa A, Shimono N, Nagasaki
- 534 Y, Minami R, Toya T, Sekiya N, Fukuhara T, Matsuura Y, Schreiber G, Ikeda T,
- 535 Nakagawa S, Ueno T, Sato K: SARS-CoV-2 spike L452R variant evades cellular
- immunity and increases infectivity. Cell Host Microbe 2021, 29:1124-1136.e1111
- [33] Li Q, Wu J, Nie J, Zhang L, Hao H, Liu S, Zhao C, Zhang Q, Liu H, Nie L, Qin H,
- 538 Wang M, Lu Q, Li X, Sun Q, Liu J, Zhang L, Li X, Huang W, Wang Y: The Impact of
- 539 Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell 2020,
- 540 182:1284-1294 e1289
- [34] Ulloa AC, Buchan SA, Daneman N, Brown KA: Early estimates of SARS-CoV-2
- 542 Omicron variant severity based on a matched cohort study, Ontario, Canada. medRxiv
- 543 2021. [Preprint]. doi:2021.2012.2024.21268382
- [35] Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG,
- 545 Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender

- 546 N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao N-y,
- 547 Parboosing R, Wadula J, Hussey H, Davies M-A, Boulle A, von Gottberg A, Cohen C:
- 548 Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South
- 549 Africa. medRxiv 2021. [Preprint]. doi:2021.2012.2021.21268116
- 550 [36] SARS-CoV-2 variants of concern and variants under investigation in England
- 551 Technical briefing: Update on hospitalisation and vaccine effectiveness for Omicron
- 552 VOC-21NOV-01 (B.1.1.529) UK Health Security: UK Health Security, 2021.
- [37] Bentley EG, Kirby A, Sharma P, Kipar A, Mega DF, Bramwell C, Penrice-Randal R,
- 554 Prince T, Brown JC, Zhou J, Screaton GR, Barclay WS, Owen A, Hiscox JA, Stewart
- JP: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B
- and Delta variants strains in a mouse model of severe COVID-19. bioRxiv 2021.
- 557 [Preprint]. doi:2021.2012.2026.474085
- [38] Abdelnabi R, Foo CS, Zhang X, Lemmens V, Maes P, Slechten B, Raymenants J,
- 559 André E, Weynand B, Dallemier K, Neyts J: The omicron (B.1.1.529) SARS-CoV-2
- variant of concern does not readily infect Syrian hamsters. bioRxiv 2021. [Preprint].
- 561 doi:2021.2012.2024.474086
- [39] Diamond M, Peter H, Tadashi M, Kiyoko I-H, Shun I, Maki K, et al.: The SARS-
- 563 CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and
- hamsters Nature Portfolio 2022. 29 December 2021. [Preprint].
- 565 doi:https://doi.org/10.21203/rs.3.rs-1211792/v1
- [40] McMahan K, Giffin V, Tostanoski L, Chung B, Siamatu M, Suthar M, Halfmann P,
- 567 Kawaoka Y, Piedra-Mora C, Martinot A, Kar S, Andersen H, Lewis MG, Barouch DH:

- 568 Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. bioRxiv 2022.
- 569 [Preprint]. doi:2022.2001.2002.474743

570



573 Figure 1 Epidemiologic curve showing five COVID-19 disease waves in Houston 574 Methodist patients. Number of new COVID-19 cases (y-axis) totals are shown as a +/-575 three-day moving average. Each of the five waves is shown in a different color. The first and second waves were composed of a heterogenous array of SARS-CoV-2 genotypes. 576 577 The Alpha VOC shown in the third wave, the Delta VOC shown in the fourth, and the 578 Omicron VOC shown in the fifth wave indicate their numeric prominence in those 579 waves. The figure should not be interpreted to mean that all cases in the third, fourth, 580 and fifth waves were caused by Alpha, Delta, and Omicron VOCs, respectively. Rather, they are the dominant single VOCs causing disease in Houston Methodist system 581 582 patients in those waves. The fifth wave shown includes data through December 20, 583 2021. The figure was generated with Tableau version 2021.2.7 (Tableau Software, LLC, 584 Seattle, WA), and is a modified version of one presented recently⁶. The curve is 585 essentially superimposable on COVID-19 activity in all metropolitan Houston, Texas.



586

Figure 2 Increase in Omicron frequency over time and distribution in metropolitan 587 Houston. The study time frame was November 27, 2021 through December 20, 2021. 588 A: Omicron logistic growth model. The estimated case doubling time is 1.8 days. B: 589 590 Cumulative increase in Omicron during the study period; y-axis is the cumulative 591 number of new COVID-19 Omicron cases. At the end of the study period, Omicron 592 caused 90% of all COVID-19 cases. C – E: Geospatial distribution of Omicron based on 593 home address zip code for each patient. C: November 27 – December 3; D: November 27 – December 10; E: November 27 – December 20. Note differences in heat map 594 595 scale for each panel. Figures were generated using Tableau version 2021.2.7. (Tableau 596 Software, LLC, Seattle, WA).

597 Table 1. Summary of pertinent patient metadata for 4,470 unique patients infected

598 with Omicron or Alpha variants.

	Omicron Variant	Alpha Variant	Total	Statistical Analysis
No. (%) with data	1313 (29.4%)	3157 (70.6%)	4470	
Patient Characteristics		L	I	
Median Age (Years)	39.2	50.0	46.8	<i>P</i> <0.0001
				Mann-Whitney
Female	763 (58.1%)	1622 (51.4%)	2385 (53.4%)	<i>P</i> <0.0001
Male	550 (41.9%)	1535 (48.6%)	2085 (46.6%)	Fisher's exact test
Ethnicity	I		I	I
Caucasian	406 (31.0%)	1241 (39.5%)	1647 (37.0%)	<i>P</i> <0.0001
Hispanic or Latino	230 (17.6%)	945 (30.1%)	1175 (26.4%)	Chi-square
Black	544 (41.6%)	732 (23.3%)	1276 (28.7%)	
Asian	49 (3.7%)	123 (3.9%)	172 (3.9%)	-
Other	7 (0.5%)	32 (1.0%)	39 (0.9%)	-
Unavailable	77 (5.9%)	84 (2.7%)	161 (3.6%)	-
BMI		I	I	
Median BMI	28.6	30.5	30.0	<i>P</i> <0.0001
				Mann-Whitney
Admission Data				
Admitted	193 (14.7%)	1721 (54.5%)	1914 (42.8%)	<i>P</i> <0.0001
Not Admitted	1120 (85.3%)	1436 (45.5%)	2556 (57.2%)	Fisher's exact test
				Odds Ratio:
				0.144 (95% CI 0.122-
				0.170)
Median LOS (Days)	3.0	5.1	5.0	<i>P</i> <0.0001
(Discharged patients only)				Mann-Whitney
Max Respiratory Support	1	1	1	1
ECMO	1 (0.5%)	7 (0.4%)	8 (0.4%)	<i>P</i> <0.0001
Mechanical Ventilation	10 (5.2%)	144 (8.4%)	154 (8.0%)	Chi-square

Non-Invasive Ventilation	16 (8.3%)	164 (9.5%)	180 (9.4%)	
High Flow Oxygen	18 (9.3%)	364 (21.2%)	382 (20.0%)	
Low Flow Oxygen	60 (31.1%)	722 (42.0%)	782 (40.9%)	
Room Air	88 (45.6%)	320 (18.6%)	408 (21.3%)	
Mortality			L	
Alive	1302 (99.2%)	2987 (94.6%)	4289 (96.0%)	<i>P</i> <0.0001
Deceased	11 (0.8%)	170 (5.4%)	181 (4.0%)	Fisher's exact test
				Odds Ratio
				0.148 (95% CI 0.080-
				0.274)
Median PCR Cycle Thresho	ld			
Abbott Alinity	19.2	22.4	n=1569	<i>P</i> <0.0001
	n=519	n=1050		Mann-Whitney
Hologic Panther	22.0	24.2	n=447	<i>P</i> =.0950
	n=88	n=359		Mann-Whitney
Vaccine				
Not Fully Vaccinated	638 (48.6%)	3056 (96.8%)	3694 (82.6%)	<i>P</i> <0.0001
Fully Vaccinated	675 (51.4%)	101 (3.2%)	776 (17.4%)	Fisher's exact test
				Odds Ratio:
				32.012 (95% CI 25.541-
				40.123)

BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay

600 Table 2. Summary of pertinent patient metadata for 16,995 unique patients

601 infected with Omicron or Delta variants.

	Omicron Variant	Delta Variant	Total	Statistical Analysis
No. (%) with data	1313 (7.7%)	15682 (92.3%)	16995	
Patient Characteristics	1	I		I
Median Age (Years)	39.2	48.2	47.5	<i>P</i> <0.0001
				Mann-Whitney
Female	763 (58.1%)	8109 (51.7%)	8872 (52.2%)	<i>P</i> =0.0001
Male	550 (41.9%)	7573 (48.3%)	8123 (47.8%)	Fisher's exact test
Ethnicity				
Caucasian	406 (30.9%)	6874 (43.8%)	7280 (42.8%)	<i>P</i> <0.0001
Hispanic or Latino	230 (17.5%)	4166 (26.6%)	4396 (25.9%)	Chi-square
Black	544 (41.4%)	3450 (22.0%)	3994 (23.5%)	
Asian	49 (3.7%)	527 (3.4%)	576 (3.4%)	
Other	7 (0.5%)	112 (0.7%)	119 (0.7%)	
Unavailable	77 (5.9%)	553 (3.5%)	630 (3.7%)	•
BMI	1	I		I
Median BMI	28.6	29.5	29.5	<i>P</i> =0.0001
				Mann-Whitney
Admission Data				
Admitted	193 (14.7%)	6749 (43.0%)	6942 (40.8%)	<i>P</i> <0.0001
Not Admitted	1120 (85.3%)	8933 (57.0%)	10053 (59.2%)	Fisher's exact test
				Odda Datiar
				0.228 (95% CI 0.195-
Madian I OO (Dava)		5.4	5.0	0.207)
Median LOS (Days)	3.0	5.4	5.3	P<0.0001
(Discharged patients only)				Mann-whitney
Max Respiratory Support				
ECMO	1 (0.5%)	19 (0.3%)	20 (0.3%)	<i>P</i> <0.0001
Mechanical Ventilation	10 (5.2%)	723 (10.7%)	733 (10.6%)	Chi-square

Non-Invasive Ventilation	16 (8.3%)	638 (9.5%)	654 (9.4%)	
High Flow Oxygen	18 (9.3%)	1785 (26.4%)	1803 (26.0%)	
Low Flow Oxygen	60 (31.1%)	2282 (33.8%)	2342 (33.7%)	
Room Air	88 (45.6%)	1302 (19.3%)	1390 (20.0%)	
Mortality				
Alive	1302 (99.2%)	14855 (94.7%)	16157 (95.1%)	<i>P</i> <0.0001
Deceased	11 (0.8%)	827 (5.3%)	838 (4.9%)	Fisher's exact test
				Odds Ratio:
				0.152 (95% CI 0.083-
				0.276)
Median PCR Cycle Thresho	ld			
Abbott Alinity	19.2	21.43	n=5621	<i>P</i> <0.0001
	n=519	n=5102		Mann-Whitney
Hologic Panther	22.0	22.6	n=1383	<i>P</i> =.8987
	n=88	n=1295		Mann-Whitney
Vaccine				
No vaccine	584 (44.5%)	11387 (72.6%)	11971 (70.4%)	<i>P</i> <0.0001
>7 days past 1st Vaccine	54 (4.1%)	492 (3.1%)	546 (3.2%)	Chi-square
>14 days past 2nd Vaccine	535 (40.7%)	3665 (23.4%)	4200 (24.7%)	
>14 days past 3rd Vaccine	140 (10.7%)	138 (0.9%)	278 (1.6%)	

602

BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay